文献速递糖尿病肥胖与代谢综合征

术前β细胞功能对胃旁路术后2型糖尿病缓解的预测价值

Preintervention Clinical Determinants and Measured β-Cell Function as Predictors of Type 2 Diabetes Remission After Roux-en-Y Gastric Bypass Surgery.
PubMed 文献 · Diabetes Care · 2021-01-01

该研究在73例重度肥胖合并2型糖尿病患者中,评估术前口服和静脉葡萄糖刺激后的β细胞功能是否能在既有临床模型基础上提升对胃旁路术后1年糖尿病缓解的预测。结果显示,术前β细胞葡萄糖敏感性虽与糖尿病病程、HbA1c、胰岛素使用及DiaRem/Ad-DiaRem评分相关,但将其加入临床模型并未改善预测能力。

要点

  • 术前β细胞葡萄糖敏感性与糖尿病病程、HbA1c、胰岛素使用及缓解评分负相关(P<0.001)。
  • 口服葡萄糖后测得的β细胞功能是静脉刺激的1.6倍,且与术前临床代谢特征相关性更强。
  • 将术前β细胞功能加入含DiaRem/Ad-DiaRem的临床模型未提升术后1年糖尿病缓解预测力。

核心结论

  • 在已定义的临床预测模型基础上,加入术前实测β细胞功能并未增加对胃旁路术后1年糖尿病缓解的预测价值。

研究设计与样本

  • 前瞻性评估73例重度肥胖合并2型糖尿病患者在胃旁路术前及术后1年的临床特征、代谢标志物及口服和静脉葡萄糖刺激后的β细胞功能。
  • 采用单因素和多因素分析,以术前变量确定糖尿病缓解的最佳预测模型。

主要发现

  • 术前β细胞葡萄糖敏感性(β细胞功能替代指标)与已知糖尿病病程、HbA1c、胰岛素使用及DiaRem和Ad-DiaRem评分均呈负相关(均P<0.001)。
  • 口服葡萄糖后测得的β细胞功能为静脉葡萄糖刺激后的1.6倍,且与术前临床和代谢特征相关性更强。
  • 将术前β细胞功能加入包含明确糖尿病缓解评分的临床模型,未改善模型对胃旁路术后糖尿病缓解的预测能力。

临床怎么用

  • 在评估胃旁路术后糖尿病缓解概率时,现有临床评分模型(如DiaRem/Ad-DiaRem)已足够,无需常规加测术前β细胞功能来提升预测。

局限性

  • 样本量较小(73例),可能限制统计效能和结论外推。
  • 仅评估术后1年缓解,未观察更长期结局。
  • β细胞功能测量方法(口服与静脉葡萄糖刺激)的差异可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Bariatric surgery results in improved glycemic control in individuals with type 2 diabetes. Single and clusters of clinical determinants have been identified as presurgery predictors of postsurgery diabetes remission. Our goal was to assess whether the addition of measured preoperative β-cell function would improve established clinical models of prediction of diabetes remission. RESEARCH DESIGN AND METHODS: Presurgery clinical characteristics, metabolic markers, and β-cell function after oral and intravenous (IV) glucose challenges were assessed in 73 individuals with severe obesity and type 2 diabetes and again 1 year after gastric bypass surgery. Single and multivariate analyses were conducted with preoperative variables to determine the best predictive models of remission. RESULTS: Presurgery β-cell glucose sensitivity, a surrogate of β-cell function, was negatively correlated with known diabetes duration, HbA1c, insulin use, and the diabetes remission scores DiaRem and advanced (Ad)-DiaRem (all P < 0.001). Measured β-cell function after oral glucose was 1.6-fold greater than after the IV glucose challenge and more strongly correlated with preoperative clinical and metabolic characteristics. The addition of preoperative β-cell function to clinical models containing well-defined diabetes remission scores did not improve the model's ability to predict diabetes remission after Roux-en-Y gastric bypass. CONCLUSIONS: The addition of measured β-cell function does not add predictive value to defined clinical models of diabetes remission 1 year after surgical weight loss.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ligon C, Shah A, Prasad M, et al. Preintervention Clinical Determinants and Measured β-Cell Function as Predictors of Type 2 Diabetes Remission After Roux-en-Y Gastric Bypass Surgery. Diabetes Care. 2021. PMID: 34400479. doi:10.2337/dc21-0395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。